← All trials
NCT04041765
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2019
- Primary completion
- Jun 30, 2020
- Completion date
- Aug 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of IndonesiaLead sponsor
- University of IndonesiaReponsible party - principal investigator
- University of IndonesiaOverall official - principal investigator
- University of IndonesiaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.